Volume 23 Issue 11
Nov.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(11): 1869-1873
WANG Zhenlei, GAO Xuefeng, FAN Jian, YANG Fang, HAN Yiping. Analysis of comorbidities and survival of patients with advanced lung squamous cell carcinoma[J]. Chinese Journal of General Practice, 2025, 23(11): 1869-1873. doi: 10.16766/j.cnki.issn.1674-4152.004248
Citation: WANG Zhenlei, GAO Xuefeng, FAN Jian, YANG Fang, HAN Yiping. Analysis of comorbidities and survival of patients with advanced lung squamous cell carcinoma[J]. Chinese Journal of General Practice, 2025, 23(11): 1869-1873. doi: 10.16766/j.cnki.issn.1674-4152.004248
shu

Analysis of comorbidities and survival of patients with advanced lung squamous cell carcinoma

doi: 10.16766/j.cnki.issn.1674-4152.004248
  • 1.

    Department of General Practice, the First Affiliated Hospital of Naval Medical University, Shanghai 200433, China

Funds:

 19411970600

  • Received Date: 2024-11-05
    Available Online: 2026-01-07
    Abstract
  •   Objective  To analyze the clinical characteristics and comorbidities of patients with advanced lung squamous cell carcinoma and to explore the prognostic factors of patients with advanced lung cancer.  Methods  Clinical data of patients with advanced lung squamous cell carcinoma admitted to the Department of Respiratory Medicine from January 2017 to December 2021 were retrospectively analyzed, with follow-up completed in August 2023. Variables including gender, age, symptoms, smoking status, cancer stage, treatment status, and survival time of patients were statistically analyzed. The simplified comorbidity score (SCS) was used to quantitatively evaluate comorbidities. Kaplan-meier method was used to draw the overall survival (OS) survival curve of patients, and univariate and multivariate Cox regression analyses were used to analyze the predictive ability of OS and to identify prognostic factors in patients with advanced lung squamous cell carcinoma.  Results  A total of 247 patients were included, with an average age of 65.57 years, 217 cases were male, 30 cases were female, 193 cases had a smoking history, and 197 died during follow-up. In this study, the median score of SCS was 8 points (range 0-15), and significant differences in survival were observed among groups with different SCS assessments (P < 0.05). Univariate analysis showed that gender, smoking history, fibrinogen, PS score, immunotherapy, SCS score, and chronic lung disease were influencing factors of OS (P < 0.05). Multivariate Cox regression analysis showed that smoking history, fibrinogen, PS score, immunotherapy, SCS score, and chronic lung disease were independent factors affecting OS in patients with advanced lung squamous cell carcinoma.  Conclusion  The simplified comorbidity score and the presence of chronic lung disease are independent risk factors for OS in patients with advanced lung squamous cell carcinoma.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33.
    [2]
    CHENG Z, CHEN L Z, DONG X F. Long-term response to first-line treatment with sintilimab plus chemotherapy in a patient with advanced lung squamous cell carcinoma: a case report[J]. Asian J Surg, 2024. DOI: 10.1016/j.asjsur.2024.10.181.
    [3]
    YASUNORI M, SHIGERU T, TOSHIHIRO M, et al. Multicenter, retrospective study to evaluate necitumumab plus cisplatin and gemcitabine after immune checkpoint inhibitors in advanced squamous cell lung cancer in Japan: the NINJA study[J]. JTO Clin Res Rep, 2023, 4(12): 100593. DOI: 10.1016/j.jtocrr.2023.100593.
    [4]
    ANDREAS M N, BÖHMER D, PRATSCHKE J, et al. Advanced lung cancer patient benefits from minimally invasive costal resection and reconstruction: an effective palliative approach for costal metastasis[J]. J Cardiothorac Surg, 2023, 18(1): 310. DOI: 10.1186/s13019-023-02422-y.
    [5]
    中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J]. 中华肿瘤杂志, 2021, 43(6): 591-621.

    Oncology Society of Chinese Medical Association, Chinese Medical Association Publishing House. Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2021 edition)[J]. Chinese Journal of Oncology, 2021, 43(6): 591-621.
    [6]
    SHIGERU T, HIROSHIGE Y, EISAKU M, et al. MO57-5 multicenter retrospective study to evaluate necitumumab plus CDDP/GEM after ICIs in advanced squamous-cell lung cancer in Japan (NINJA study)[J]. Ann Oncol, 2023, 34(S3): S1432. DOI: 10.1016/j.annonc.2023.09.297.
    [7]
    GAO X F, WANG Z L, LIU J, et al. Impact of COPD pulmonary structural remodeling on the prognosis of patients with advanced lung squamous cell carcinoma[J]. Heliyon, 2023, 9(11): e22042. DOI: org/ 10.1016/j.heliyon.2023.e22042.
    [8]
    JIANG M L, SUN J Y, HU C L, et al. A tumor cornification and immune-infiltration-based scheme for anti-PD-1 plus chemotherapy response in advanced squamous cell lung carcinoma[J]. Med, 2025, 6(2): 100516. DOI: 10.1016/j.medj.2024.09.005.
    [9]
    YOSHIOKA H, MORI K, ISHIKAWA N, et al. 1357P Multicenter phase Ⅱ study of cisplatin and gemcitabine plus necitumumab in patients with unresectable, advanced lung squamous cell carcinoma who have progressed on orafter initial treatment with immune checkpoint inhibitors plus platinum-based chemotherapy: WJOG14120L NESSIE study[J]. Ann Oncol, 2024, 35(S2): S855-S856.
    [10]
    DELMONTE A, BONANNO L, LANDI L, et al. EP08.01-030 nivolumab+ipilimumab vs platinum-based CT+nivolumab in advanced lung squamous-cell carcinoma: the randomized SQUINT trial[J]. J Thorac Oncol, 2022, 17(9S): S351. DOI: 10.1016/j.jtho.2022.07.602.
    [11]
    SANTOS E S, RODRIGUEZ E. Treatment considerations for patients with advanced squamous cell carcinoma of the lung: a plain language summary[J]. Lung Cancer Manag, 2022, 11(3): LMT56. DOI: 10.2217/lmt-2022-0017.
    [12]
    KOZONO D, HUA X, WU C M, et al. Lung-MAP next generation sequencing analysis of advanced squamous cell lung cancers (SWOG S1400)[J]. J Thorac Oncol, 2024, 19(12): 1618-1629. doi: 10.1016/j.jtho.2024.07.024
    [13]
    MEDIA A S, PERSSON M, TAJHIZI N, et al. Chronic obstructive pulmonary disease and comorbidities ' influence on mortality in non-small cell lung cancer patients[J]. Acta Oncol, 2019, 58(8): 1102-1106. doi: 10.1080/0284186X.2019.1612942
    [14]
    ZHAI R H, YU X J, SHAFER A, et al. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection[J]. Chest, 2014, 145(2): 346-353. doi: 10.1378/chest.13-1176
    [15]
    YUSUKE T, KAZUHITO F, AKIKAZU K, et al. Left upper lobectomy with combined distal aortic arch and left subclavian artery resection after neoadjuvant chemoradiotherapy for locally advanced lung squamous cell carcinoma[J]. Respirol Case Rep, 2022, 10(8): e0994. DOI: 10.1002/rcr2.994.
    [16]
    IACHINA M, JAKOBSEN E, MØLLER H, et al. The effect of different comorbidities on survival of non-small cells lung cancer patients[J]. Lung, 2015, 193(2): 291-297. doi: 10.1007/s00408-014-9675-5
    [17]
    刘允, 刘莹, 刘佳慧, 等. 阿法替尼二线治疗晚期肺鳞癌患者的效果观察[J]. 中华全科医学, 2024, 22(9): 1491-1495, 1499. doi: 10.16766/j.cnki.issn.1674-4152.003666

    LIU Y, LIU Y, LIU J H, et al. Clinical efficacy of afatinib in second-line treatment of advanced squamous cell carcinoma of the lung[J]. Chinese Journal of General Practice, 2024, 22(9): 1491-1499. doi: 10.16766/j.cnki.issn.1674-4152.003666
    [18]
    SCHREUDER A, JACOBS C, GALLARDO E L, et al. Predicting all-cause and lung cancer mortality using emphysema score progression rate between baseline and follow-up chest CT images: a comparison of risk model performances[J]. PLoS One, 2019, 14(2): e0212756. DOI: 10.1371/journal.pone.0212756.
    [19]
    AJIMIZU H, OZASA H, SATO S, et al. Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer[J]. Sci Rep, 2021, 11(1): 23677. DOI: 10.1038/s41598-021-03139-5.
    [20]
    JO H, PARK S, KIM N E, et al. Impact of COPD treatment on survival in patients with advanced non-small cell lung cancer[J]. J Clin Med, 2022, 11(9): 2391. DOI: 10.3390/jcm11092391.
    [21]
    KASEDA K, HISHIDA T, MASAI K, et al. Clinicopathological and prognostic features of operable non-small cell lung cancer patients with diabetes mellitus[J]. J Surg Oncol, 2021, 123(1): 332-341. doi: 10.1002/jso.26243
    [22]
    JACOBI O, LANDMAN Y, REINHORN D, et al. The relationship of diabetes mellitus to efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer[J]. Oncology, 2021, 99(9): 555-561. doi: 10.1159/000516671
    [23]
    OSAWA K, BESSHO A, FUKE S, et al. Coronary artery calcification scoring system based on the coronary artery calcium data and reporting system (CAC-DRS) predicts major adverse cardiovascular events or all-cause death in patients with potentially curable lung cancer without a history of cardiovascular disease[J]. Heart Vessels, 2020, 35(11): 1483-1493. doi: 10.1007/s00380-020-01624-x
    [24]
    蒋旭, 苗雷, 杨琳, 等. 小细胞肺癌影像诊断研究进展[J]. 中华全科医学, 2024, 22(2): 296-300. doi: 10.16766/j.cnki.issn.1674-4152.003388

    JIANG X, MIAO L, YANG L, et al. Advances in diagnostic imaging of small cell lung cancer[J]. Chinese Journal of General Practice, 2024, 22(2): 296-300. doi: 10.16766/j.cnki.issn.1674-4152.003388
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (39) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return